Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment

Nir Modiano, Lauren B. Gerson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Barrett's esophagus is a metaplastic alteration of the normal esophageal epithelium that is detected on endoscopic examination and pathologically confirmed by the presence of intestinal metaplasia on biopsy. Its major significance is as a predisposing factor for esophageal adenocarcinoma, which carries a high mortality rate and a rapidly growing incidence in the United States. Detection of Barrett's esophagus allows for endoscopic surveillance in order to detect the potential development of dysplasia and early cancer before symptoms develop, and thereby significantly increases treatment options and may lower mortality from esophageal adenocarcinoma. Much current work in the field is aimed at reducing the risk of progression from Barrett's esophagus to cancer, and in the identification of biomarkers that may predict progression towards cancer. Barrett's esophagus is present in 10%-20% of patients with gastroesophageal reflux disease (GERD) and has also been detected in patients who deny classic GERD symptoms and are undergoing endoscopy for other indications. We used an evidence-based approach to describe treatment options for patients with Barrett's esophagus.

Original languageEnglish (US)
Pages (from-to)1035-1045
Number of pages11
JournalTherapeutics and Clinical Risk Management
Volume3
Issue number6
StatePublished - 2007
Externally publishedYes

Fingerprint

Barrett Esophagus
etiology
cancer
incidence
Endoscopy
Biopsy
Incidence
Biomarkers
mortality
Disease
development potential
Gastroesophageal Reflux
Adenocarcinoma
surveillance
indication
Therapeutics
Mortality
Metaplasia
Esophageal Neoplasms
examination

Keywords

  • Barrett's esophagus
  • Endoscopic surveillance
  • Esophageal adenocarcinoma
  • Evidence-based approach

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Barrett's esophagus : Incidence, etiology, pathophysiology, prevention and treatment. / Modiano, Nir; Gerson, Lauren B.

In: Therapeutics and Clinical Risk Management, Vol. 3, No. 6, 2007, p. 1035-1045.

Research output: Contribution to journalArticle

@article{397c9bd5da7c47fc89cf158c59c936de,
title = "Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment",
abstract = "Barrett's esophagus is a metaplastic alteration of the normal esophageal epithelium that is detected on endoscopic examination and pathologically confirmed by the presence of intestinal metaplasia on biopsy. Its major significance is as a predisposing factor for esophageal adenocarcinoma, which carries a high mortality rate and a rapidly growing incidence in the United States. Detection of Barrett's esophagus allows for endoscopic surveillance in order to detect the potential development of dysplasia and early cancer before symptoms develop, and thereby significantly increases treatment options and may lower mortality from esophageal adenocarcinoma. Much current work in the field is aimed at reducing the risk of progression from Barrett's esophagus to cancer, and in the identification of biomarkers that may predict progression towards cancer. Barrett's esophagus is present in 10{\%}-20{\%} of patients with gastroesophageal reflux disease (GERD) and has also been detected in patients who deny classic GERD symptoms and are undergoing endoscopy for other indications. We used an evidence-based approach to describe treatment options for patients with Barrett's esophagus.",
keywords = "Barrett's esophagus, Endoscopic surveillance, Esophageal adenocarcinoma, Evidence-based approach",
author = "Nir Modiano and Gerson, {Lauren B.}",
year = "2007",
language = "English (US)",
volume = "3",
pages = "1035--1045",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Barrett's esophagus

T2 - Incidence, etiology, pathophysiology, prevention and treatment

AU - Modiano, Nir

AU - Gerson, Lauren B.

PY - 2007

Y1 - 2007

N2 - Barrett's esophagus is a metaplastic alteration of the normal esophageal epithelium that is detected on endoscopic examination and pathologically confirmed by the presence of intestinal metaplasia on biopsy. Its major significance is as a predisposing factor for esophageal adenocarcinoma, which carries a high mortality rate and a rapidly growing incidence in the United States. Detection of Barrett's esophagus allows for endoscopic surveillance in order to detect the potential development of dysplasia and early cancer before symptoms develop, and thereby significantly increases treatment options and may lower mortality from esophageal adenocarcinoma. Much current work in the field is aimed at reducing the risk of progression from Barrett's esophagus to cancer, and in the identification of biomarkers that may predict progression towards cancer. Barrett's esophagus is present in 10%-20% of patients with gastroesophageal reflux disease (GERD) and has also been detected in patients who deny classic GERD symptoms and are undergoing endoscopy for other indications. We used an evidence-based approach to describe treatment options for patients with Barrett's esophagus.

AB - Barrett's esophagus is a metaplastic alteration of the normal esophageal epithelium that is detected on endoscopic examination and pathologically confirmed by the presence of intestinal metaplasia on biopsy. Its major significance is as a predisposing factor for esophageal adenocarcinoma, which carries a high mortality rate and a rapidly growing incidence in the United States. Detection of Barrett's esophagus allows for endoscopic surveillance in order to detect the potential development of dysplasia and early cancer before symptoms develop, and thereby significantly increases treatment options and may lower mortality from esophageal adenocarcinoma. Much current work in the field is aimed at reducing the risk of progression from Barrett's esophagus to cancer, and in the identification of biomarkers that may predict progression towards cancer. Barrett's esophagus is present in 10%-20% of patients with gastroesophageal reflux disease (GERD) and has also been detected in patients who deny classic GERD symptoms and are undergoing endoscopy for other indications. We used an evidence-based approach to describe treatment options for patients with Barrett's esophagus.

KW - Barrett's esophagus

KW - Endoscopic surveillance

KW - Esophageal adenocarcinoma

KW - Evidence-based approach

UR - http://www.scopus.com/inward/record.url?scp=38049144955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049144955&partnerID=8YFLogxK

M3 - Article

C2 - 18516262

AN - SCOPUS:38049144955

VL - 3

SP - 1035

EP - 1045

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 6

ER -